Core Viewpoint - Hims & Hers Health Inc. is gaining attention in the healthcare sector due to its unique combination of health services and technology-driven growth, positioning it as a potential investment opportunity [1] Company Overview - Hims & Hers Health stock is currently priced at $62.57, reflecting a decline of 5.45% [2] - The stock has a 52-week range between $13.47 and $72.98, with a P/E ratio of 90.68 and a price target of $39.83 [2] Market Context - The recent association of Hims & Hers with weight loss products is linked to the broader market trend, particularly the "Ozempic boom" [2] - Despite this association, the company was already on a growth trajectory prior to entering the weight loss market [3] Competitive Landscape - Shares of Novo Nordisk have dropped by 31% in the past month due to regulatory scrutiny, which may impact Hims & Hers due to correlation in the market [4][5] - Hims & Hers has a diversified product offering and a different business model, which may mitigate the impact of Novo Nordisk's decline [5] Business Model - Hims & Hers operates primarily through a telehealth platform, generating over 90% of its revenue from subscriptions, which provides stability and predictability in financial forecasting [6][7] - The stock still trades at 95% of its 52-week high, indicating ongoing market optimism compared to Novo Nordisk, which has fallen to 35% of its 52-week high [8] Financial Performance - Revenue for Hims & Hers surged by 111% over the past year, driven by strong demand and market share expansion [9] - The subscriber base grew to 2.4 million, a 38% increase year-over-year, highlighting the company's growth potential [10] - Free cash flow reached $50.1 million for the quarter, up nearly fivefold from $11.9 million in the same quarter last year, indicating strong compounding potential for reinvestment [13] Management Guidance - Hims & Hers management has reiterated its full-year financial guidance for 2025, contrasting with other companies that have refrained from providing guidance amid economic uncertainties [11]

Core Viewpoint - Hims & Hers Health, Inc. faces significant challenges following the termination of its collaboration with Novo Nordisk and increasing scrutiny from U.S. lawmakers regarding safety concerns related to copycat weight loss drugs [1][2][5]. Company Developments - On July 25, 2025, Hims & Hers shares dropped significantly amid reports of lawmakers urging the FDA to take action against counterfeit weight loss drugs [1]. - Novo Nordisk ended its collaboration with Hims & Hers on June 23, 2025, citing concerns over deceptive marketing practices and illegal compounding of its FDA-approved drug Wegovy® [2][6]. - The collaboration, which began on April 29, 2025, was short-lived, lasting less than two months due to regulatory compliance issues raised by Novo Nordisk [6]. Legal Issues - Following Novo Nordisk's announcement, securities class action lawsuits were filed against Hims & Hers and its executives, representing investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [3][7]. - Legal claims allege that Hims & Hers misled investors regarding its regulatory compliance and the revenue potential from its GLP-1 drug offerings [7][8]. - The lawsuits assert that Hims & Hers engaged in deceptive promotion and sale of unauthorized versions of Wegovy®, exposing patients to risks and jeopardizing its relationship with Novo Nordisk [8][9]. Industry Context - Over 80 bipartisan lawmakers have expressed concerns about the rise of illegal and counterfeit anti-obesity medications, emphasizing the potential risks to patient safety [5]. - The scrutiny from lawmakers and the legal actions against Hims & Hers highlight the increasing regulatory pressures in the weight loss drug market, particularly concerning compliance and marketing practices [5][6].

RADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25, ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - A second complaint with similar claims has also been filed against Hims & Hers [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy on its platform, which contains the active ingredient semaglutide [3]. Group 3: Allegations and Stock Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could sell both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

Core Insights - Hims & Hers Health, Inc. is developing a digital-first healthcare platform focused on personalization, accessibility, and scalability, integrating telehealth, electronic medical records, cloud pharmacy fulfillment, and AI-driven care routing [1][3] - The company has reached 2.4 million subscribers in Q1 2025, with over 1.4 million utilizing personalized health solutions, indicating strong demand for tech-enabled care [1][7] - Hims & Hers is investing heavily in AI, appointing Mo Elshenawy as CTO to enhance diagnostics and platform personalization, supported by an $870 million convertible notes offering for AI innovation and global expansion [2][7] Company Strategy - Hims & Hers is vertically integrating operations through acquisitions in pharmacy and diagnostics, improving control over fulfillment and care quality [3] - The company employs tools like MedMatch to optimize patient care pathways and is developing AI applications to automate diagnosis and treatment recommendations [3] Market Performance - Hims & Hers shares have increased by 171% year to date, significantly outperforming the industry growth of 10.7% [6] - The forward 12-month price-to-sales ratio for Hims & Hers is 5.6X, lower than the industry average of 5.8X but higher than its three-year median of 2.3X [8] Earnings Estimates - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share indicates a 177.8% improvement from 2024 [9] - Current estimates for the upcoming quarters show significant year-over-year growth, with EPS expected to rise from $0.06 in the previous year to $0.75 in 2025 [12]

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect th ...

Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the implications for Hims subscribers' access to the weight-loss drug Wegovy [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Key Takeaways Hims & Hers Health, Inc. (HIMS) is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the last reported quarter, the company's earnings per share (EPS) of 20 cents topped the Zacks Consensus Estimate by 66.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on two occasions, missed once and broke even in the other, delivering an earnings surprise of 19.6%, on average. Let's check out the factors that have shaped HIMS' p ...